Income Statement (TTM)
Keros Therapeutics, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 0 | 0 | 20 | 20 | 20 | 20 | 0 | 0 | 0 | 0 | 1 | 4 | 215 | 233 |
| Change (%) | -96.00 | 0.00 | 20,000.00 | 0.00 | -0.50 | 0.00 | -99.96 | 1,787.50 | 54.97 | 15.81 | 140.22 | 445.31 | 5,948.25 | 8.44 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 28 | 40 | 46 | 55 | 62 | 75 | 81 | 123 | 7 | 15 | 165 | 10 | 13 | ||
| Change (%) | 39.66 | 16.28 | 19.92 | 11.94 | 21.54 | 8.27 | 50.97 | 111.36 | 992.49 | 28.59 | |||||
| % of Revenue | 1,132.64 | 39,547.00 | 45,984.00 | 274.34 | 307.09 | 375.12 | 406.15 | 1,532,900.00 | 3,062.82 | 5,589.67 | 25,421.04 | 4.87 | 5.77 | ||
| Gross Operating Profit | -26 | -39 | -46 | -35 | -42 | -55 | -61 | -123 | 0 | -7 | -15 | -165 | 4 | 204 | 219 |
| Change (%) | 52.80 | 16.32 | -23.63 | 18.79 | 32.19 | 11.28 | 100.26 | -100.12 | -4,691.39 | 114.58 | 1,008.02 | -102.15 | 5,653.86 | 7.41 | |
| % of Revenue | -1,032.64 | -39,447.00 | -45,884.00 | -174.34 | -207.09 | -275.12 | -306.15 | -1,532,800.00 | 100.00 | -2,962.82 | -5,489.67 | -25,321.04 | 100.00 | 95.13 | 94.23 |
| SG&A | 10 | 17 | 19 | 21 | 23 | 25 | 26 | 33 | 35 | 37 | 39 | 39 | 41 | 41 | 45 |
| Change (%) | 66.90 | 10.60 | 12.77 | 8.32 | 7.74 | 6.32 | 24.02 | 6.13 | 7.26 | 3.10 | 1.74 | 3.98 | 0.46 | 11.04 | |
| % of Revenue | 409.88 | 17,102.00 | 18,914.00 | 106.12 | 114.95 | 124.47 | 132.32 | 410,275.00 | 23,068.87 | 15,967.52 | 14,214.76 | 6,020.58 | 1,148.00 | 19.07 | 19.53 |
| R&D | 0 | 135 | 135 | 135 | 174 | 174 | 174 | ||||||||
| Change (%) | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| % of Revenue | 1.24 | 89,574.83 | 57,802.56 | 49,910.70 | 4,890.96 | 80.87 | 74.57 | ||||||||
| OpEx | 39 | 57 | 65 | 76 | 85 | 100 | 108 | 155 | 170 | 180 | 189 | 205 | 214 | 225 | 233 |
| Change (%) | 46.78 | 14.56 | 17.84 | 10.93 | 17.78 | 7.79 | 44.35 | 9.42 | 5.70 | 5.08 | 8.34 | 4.74 | 4.96 | 3.34 | |
| % of Revenue | 1,543.76 | 56,649.00 | 64,898.00 | 380.46 | 422.04 | 499.58 | 538.48 | 1,943,175.00 | 112,643.71 | 76,832.91 | 69,715.13 | 31,441.63 | 6,038.96 | 104.80 | 99.87 |
| Operating Income | -36 | -57 | -65 | -56 | -65 | -80 | -88 | -155 | -170 | -180 | -189 | -204 | -211 | -10 | 0 |
| Change (%) | 56.67 | 14.59 | -13.00 | 14.82 | 23.46 | 9.73 | 77.26 | 9.32 | 5.66 | 5.07 | 8.15 | 3.33 | -95.11 | -103.03 | |
| % of Revenue | -1,443.76 | -56,549.00 | -64,798.00 | -280.46 | -322.04 | -399.58 | -438.48 | -1,943,075.00 | -112,543.71 | -76,732.91 | -69,615.13 | -31,341.63 | -5,938.96 | -4.80 | 0.13 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | |||||||
| Change (%) | -16.67 | -20.00 | -0.00 | -0.00 | -25.00 | -33.33 | -100.00 | ||||||||
| % of Revenue | -0.24 | -5.00 | -4.00 | -0.02 | -0.02 | -0.01 | -0.01 | 0.00 | |||||||
| Net Income | -37 | -54 | -62 | -59 | -67 | -79 | -82 | -142 | -153 | -160 | -168 | -182 | -187 | 4 | 19 |
| Change (%) | 44.83 | 15.24 | -5.98 | 14.13 | 17.37 | 4.08 | 73.95 | 7.39 | 4.78 | 4.84 | 8.04 | 3.18 | -102.25 | 345.70 | |
| % of Revenue | -1,497.44 | -54,219.00 | -62,480.00 | -292.26 | -333.56 | -393.44 | -409.50 | -1,780,837.50 | -101,319.21 | -68,505.13 | -62,012.55 | -27,890.94 | -5,277.55 | 1.96 | 8.06 |
Source: Capital IQ
